| 1. |
Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet, 2005, 366(9503): 2087-2106.
|
| 2. |
START Trialists’ Group; Bentzen SM, Agrawal RK, et al. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol, 2008, 9(4): 331-341.
|
| 3. |
START Trialists’ Group; Bentzen SM, Agrawal RK, et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet, 2008, 371(9618): 1098-1107.
|
| 4. |
Whelan TJ, Pignol JP, Levine MN, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med, 2010, 362(6): 513-520.
|
| 5. |
Gradishar WJ, Anderson BO, Balassanian R, et al. Invasive breast cancer version 1.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 2016, 14(3): 324-354.
|
| 6. |
Correa C, Harris EE, Leonardi MC, et al. Accelerated partial breast irradiation: executive summary for the update of an ASTRO evidence-based consensus statement. Pract Radiat Oncol, 2017, 7(2): 73-79.
|
| 7. |
Strnad V, Ott OJ, Hildebrandt G, et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet, 2016, 387(10015): 229-238.
|
| 8. |
Livi L, Meattini I, Marrazzo L, et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. Eur J Cancer, 2015, 51(4): 451-463.
|
| 9. |
McCormick B, Winter K, Hudis C, et al. RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol, 2015, 33(7): 709-715.
|
| 10. |
Solin LJ, Gray R, Hughes LL, et al. Surgical excision without radiation for ductal carcinoma in situ of the breast: 12-year results from the ECOG-ACRIN E5194 study. J Clin Oncol, 2015, 33(33): 3938-3944.
|
| 11. |
Small W Jr, Thomas TO, Alvarado M, et al. Commentary on " accelerated partial breast irradiation consensus statement: update of an ASTRO evidence-based consensus statement”. Pract Radiat Oncol, 2017, 7(3): e159-e163.
|
| 12. |
Vaidya JS, Bulsara M, Wenz F, et al. Pride, prejudice, or science: attitudes towards the results of the TARGIT-A trial of targeted intraoperative radiation therapy for breast cancer. Int J Radiat Oncol Biol Phys, 2015, 92(3): 491-497.
|
| 13. |
Veronesi U, Orecchia R, Maisonneuve P, et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol, 2013, 14(13): 1269-1277.
|
| 14. |
Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol, 2013, 31(19): 2382-2387.
|
| 15. |
Kunkler IH, Williams LJ, Jack WJ, et al. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME Ⅱ): a randomised controlled trial. Lancet Oncol, 2015, 16(3): 266-273.
|
| 16. |
Veronesi U, Marubini E, Mariani L, et al. The dissection of internal mammary nodes does not improve the survival of breast cancer patients. 30-year results of a randomised trial. Eur J Cancer, 1999, 35(9): 1320-1325.
|
| 17. |
Poortmans PM, Collette S, Kirkove C, et al. Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med, 2015, 373(4): 317-327.
|
| 18. |
Whelan TJ, Olivotto IA, Parulekar WR, et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med, 2015, 373(4): 307-316.
|
| 19. |
Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol, 2014, 15(12): 1303-1310.
|
| 20. |
Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinelnode metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA, 2017, 318(10): 918-926.
|
| 21. |
Galimberti V, Cole BF, Zurrida S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol, 2013, 14(4): 297-305.
|
| 22. |
Scomersi S, Torelli L, Zanconati F, et al. Evaluation of a breast cancer nomogram for predicting the likelihood of additional nodal metastases in patients with a positive sentinel node biopsy. Ann Ital Chir, 2012, 83(6): 461-468.
|
| 23. |
Morigi C. Highlights from the 15th St Gallen International Breast Cancer Conference 15-18 March, 2017, Vienna: tailored treatments for patients with early breast cancer. Ecancermedicalscience, 2017, 11: 732.
|
| 24. |
Scott JG, Berglund A, Schell MJ, et al. A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. Lancet Oncol, 2017, 18(2): 202-211.
|
| 25. |
Rakovitch E, Nofech-Mozes S, Hanna W, et al. A population-based validation study of the DCIS score predicting recurrence risk in individuals treated by breast-conserving surgery alone. Breast Cancer Res Treat, 2015, 152(2): 389-398.
|
| 26. |
Speers C, Zhao S, Liu M, et al. Development and validation of a novel radiosensitivity signature in human breast cancer. Clin Cancer Res, 2015, 21(16): 3667-3677.
|
